LYEL Collar Strategy
LYEL (Lyell Immunopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL (Lyell Immunopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $448.9M, a beta of -0.06 versus the broader market, a 52-week range of 7.65-45, average daily share volume of 95K, a public-listing history dating back to 2021, approximately 300 full-time employees. These structural characteristics shape how LYEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.06 indicates LYEL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a collar on LYEL?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current LYEL snapshot
As of May 15, 2026, spot at $18.01, ATM IV 151.00%, IV rank 30.79%, expected move 43.29%. The collar on LYEL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this collar structure on LYEL specifically: IV regime affects collar pricing on both sides; mid-range LYEL IV at 151.00% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 43.29% (roughly $7.80 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LYEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on LYEL should anchor to the underlying notional of $18.01 per share and to the trader's directional view on LYEL stock.
LYEL collar setup
The LYEL collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LYEL near $18.01, the first option leg uses a $19.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LYEL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LYEL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $18.01 | long |
| Sell 1 | Call | $19.00 | $3.02 |
| Buy 1 | Put | $17.00 | $2.90 |
LYEL collar risk and reward
- Net Premium / Debit
- -$1,789.00
- Max Profit (per contract)
- $111.00
- Max Loss (per contract)
- -$89.00
- Breakeven(s)
- $17.89
- Risk / Reward Ratio
- 1.247
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
LYEL collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on LYEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$89.00 |
| $3.99 | -77.8% | -$89.00 |
| $7.97 | -55.7% | -$89.00 |
| $11.95 | -33.6% | -$89.00 |
| $15.93 | -11.5% | -$89.00 |
| $19.92 | +10.6% | +$111.00 |
| $23.90 | +32.7% | +$111.00 |
| $27.88 | +54.8% | +$111.00 |
| $31.86 | +76.9% | +$111.00 |
| $35.84 | +99.0% | +$111.00 |
When traders use collar on LYEL
Collars on LYEL hedge an existing long LYEL stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
LYEL thesis for this collar
The market-implied 1-standard-deviation range for LYEL extends from approximately $10.21 on the downside to $25.81 on the upside. A LYEL collar hedges an existing long LYEL position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current LYEL IV rank near 30.79% is mid-range against its 1-year distribution, so the IV signal is neutral; the collar thesis on LYEL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, LYEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LYEL-specific events.
LYEL collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LYEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LYEL alongside the broader basket even when LYEL-specific fundamentals are unchanged. Always rebuild the position from current LYEL chain quotes before placing a trade.
Frequently asked questions
- What is a collar on LYEL?
- A collar on LYEL is the collar strategy applied to LYEL (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With LYEL stock trading near $18.01, the strikes shown on this page are snapped to the nearest listed LYEL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LYEL collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the LYEL collar priced from the end-of-day chain at a 30-day expiry (ATM IV 151.00%), the computed maximum profit is $111.00 per contract and the computed maximum loss is -$89.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LYEL collar?
- The breakeven for the LYEL collar priced on this page is roughly $17.89 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LYEL market-implied 1-standard-deviation expected move is approximately 43.29%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on LYEL?
- Collars on LYEL hedge an existing long LYEL stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current LYEL implied volatility affect this collar?
- LYEL ATM IV is at 151.00% with IV rank near 30.79%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.